Mozart Therapeutics Announces Podium Presentation at Immunology of Diabetes Congress; Shows Potential for Lead Program, MTX-101, to Restore Insulin Production in Type 1 Diabetes

Preclinical data in type 1 diabetes organoid model demonstrate MTX-101 can reestablish functionality of pancreatic beta cells Phase 1 clinical study underway to evaluate MTX-101 in healthy adults and patients with celiac disease and T1D SEATTLE, Nov. 5, 2024 /PRNewswire/ — Mozart…